MKI67 and neoplasm: monarchE focused on patients with node-positive disease and additional high-risk clinical-pathologic features (e.g., tumour size ≥ 5 cm, grade 3, or Ki-67 ≥ 20%) [19], while NATALEE included a broader population, i.e., patients with stage IIA disease and high genomic risk, even in the absence of nodal involvement [20].